[A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis].
The trial of efficacy and safety of two doses of the drug cernilton in patients with chronic abacterial prostatitis made in the Research Institute of Urology and I.M. Sechenov Medical Academy in 2008 gave evidence for subjective (NIH-CPSI, Sex-4, IPSS and other scales, QOL) and objective (leucocyte count in prostatic secretion) pronounced anti-inflammatory effects of the drug which persist for at least 6 months. Comparison of the two doses of cernilton showed significant differences in subjective response of the patients (NIH-CPSI and Symptom Frequency Scale). Cernilton is recommended as a medication of choice for treatment of patients with chronic abacterial prostatitis.
Apolikhin
O I
OI
Aliaev
Iu G
IuG
Sivkov
A V
AV
Vinarov
A Z
AZ
Oshchepkov
V N
VN
Keshishev
N G
NG
Bedretdinova
D A
DA
Akhvlediani
N D
ND
D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011472:Prostatitis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012434:Secale / Q000009:adverse effects; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010936:Plant Extracts; C010070:cernilton